Allergy drug could tame gut inflammation in colitis
NCT ID NCT07064707
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether rupatadine, an allergy medicine, can help control inflammation in people with mild-to-moderate ulcerative colitis. About 60 adults will take rupatadine or a standard treatment (mesalamine) for several weeks. The goal is to see if rupatadine reduces symptoms like diarrhea and rectal bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rupatadine
- What this could lead to
- If it works, this could point toward a new oral treatment option for mild-to-moderate ulcerative colitis, helping control inflammation and symptoms.
- What could go wrong
- This is a small, early-phase trial with only 60 people. It may not show enough benefit or could have side effects. Success is far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alexandria University
RECRUITINGAlexandria, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a glass of pomegranate juice tame gut inflammation?